FARGO — A new FDA approved drug, to help people with schizophrenia, will soon be accessible for medical officials to ...
The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...
AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest telecommunications business by revenue offers a juicy 5.1% dividend yield.
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback